Last reviewed · How we verify

Addition of oral Metolazone

University of North Carolina, Chapel Hill · FDA-approved active Small molecule

Addition of oral Metolazone is a Thiazide-like diuretic Small molecule drug developed by University of North Carolina, Chapel Hill. It is currently FDA-approved for Hypertension, Edema associated with congestive heart failure, Edema associated with renal disease. Also known as: Zaroxolyn.

Metolazone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting urinary excretion of water and electrolytes.

Metolazone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting urinary excretion of water and electrolytes. Used for Hypertension, Edema associated with congestive heart failure, Edema associated with renal disease.

At a glance

Generic nameAddition of oral Metolazone
Also known asZaroxolyn
SponsorUniversity of North Carolina, Chapel Hill
Drug classThiazide-like diuretic
TargetSodium-chloride cotransporter (NCC)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Metolazone blocks the Na-Cl cotransporter in the distal convoluted tubule of the nephron, preventing reabsorption of sodium and chloride and thereby increasing urine output. This reduces blood volume and intravascular fluid, lowering blood pressure and reducing edema. It is particularly effective when combined with loop diuretics in resistant edema or heart failure due to its synergistic action at different sites of the nephron.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Addition of oral Metolazone

What is Addition of oral Metolazone?

Addition of oral Metolazone is a Thiazide-like diuretic drug developed by University of North Carolina, Chapel Hill, indicated for Hypertension, Edema associated with congestive heart failure, Edema associated with renal disease.

How does Addition of oral Metolazone work?

Metolazone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting urinary excretion of water and electrolytes.

What is Addition of oral Metolazone used for?

Addition of oral Metolazone is indicated for Hypertension, Edema associated with congestive heart failure, Edema associated with renal disease.

Who makes Addition of oral Metolazone?

Addition of oral Metolazone is developed and marketed by University of North Carolina, Chapel Hill (see full University of North Carolina, Chapel Hill pipeline at /company/university-of-north-carolina-chapel-hill).

Is Addition of oral Metolazone also known as anything else?

Addition of oral Metolazone is also known as Zaroxolyn.

What drug class is Addition of oral Metolazone in?

Addition of oral Metolazone belongs to the Thiazide-like diuretic class. See all Thiazide-like diuretic drugs at /class/thiazide-like-diuretic.

What development phase is Addition of oral Metolazone in?

Addition of oral Metolazone is FDA-approved (marketed).

What are the side effects of Addition of oral Metolazone?

Common side effects of Addition of oral Metolazone include Hypokalemia, Hyperuricemia, Hyperglycemia, Hyponatremia, Dizziness, Headache.

What does Addition of oral Metolazone target?

Addition of oral Metolazone targets Sodium-chloride cotransporter (NCC) and is a Thiazide-like diuretic.

Related